BioCardia Dirección

Dirección controles de criterios 4/4

El CEO de BioCardia's es Peter Altman , nombrado en Jan 2002, tiene una permanencia de 22.25 años. compensación anual total es $746.24K, compuesta por 69.1% salario y 30.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.08% de las acciones de la empresa, por valor de $205.60K. La antigüedad media del equipo directivo y de la junta directiva es de 8.1 años y 7.5 años, respectivamente.

Información clave

Peter Altman

Chief Executive Officer (CEO)

US$746.2k

Compensación total

Porcentaje del salario del CEO	69.1%
Permanencia del CEO	22.3yrs
Participación del CEO	2.1%
Permanencia media de la dirección	8.2yrs
Promedio de permanencia en la Junta Directiva	7.6yrs

Actualizaciones recientes de la dirección

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

Recent updates

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

BioCardia slips 11% on launch of direct offering

Dec 16

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Peter Altman en comparación con los beneficios de BioCardia?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$746k	US$516k	-US$12m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$902k	US$531k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$488k	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$883k	US$380k	-US$15m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$747k	US$363k	-US$15m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$360k	-US$14m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$372k	US$310k	-US$12m

Compensación vs. Mercado: La compensación total ($USD746.24K) de Peter está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Peter ha sido consistente con los resultados de la empresa en el último año.

CEO

Peter Altman (56 yo)

22.3yrs

Permanencia

US$746,237

Compensación

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Altman	CEO, President & Director	22.3yrs	US$746.24k	2.08% $ 210.2k
David McClung	Chief Financial Officer	8.2yrs	US$469.47k	0.51% $ 51.1k
Edward Gillis	Senior Vice President of Devices	3.6yrs	US$326.37k	0.18% $ 18.4k

8.2yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BCDA es experimentado (8.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Altman	CEO, President & Director	22.3yrs	US$746.24k	2.08% $ 210.2k
Jay Moyes	Independent Director	13.3yrs	US$65.29k	0.20% $ 20.4k
Richard Krasno	Independent Director	7.6yrs	US$57.79k	0.18% $ 17.8k
William Facteau	Independent Director	less than a year	US$24.69k	sin datos
Simon Stertzer	Independent Director	22.3yrs	US$47.55k	5.54% $ 560.4k
Jim Allen	Independent Director	4.6yrs	US$49.29k	3.33% $ 336.7k
Andrew Blank	Independent Chairman	4.6yrs	US$97.79k	1.87% $ 189.3k

7.6yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de BCDA se considera experimentada (7.5 años de antigüedad promedio).

BioCardia Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

BioCardia, Inc., Annual General Meeting, May 20, 2024

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Insider recently bought US$177k worth of stock

Recent updates

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

New major risk - Negative shareholders equity

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Consensus revenue estimates decrease by 74%, EPS upgraded

New major risk - Revenue size

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

New minor risk - Share price stability

Insider recently bought US$177k worth of stock

Consensus revenue estimates increase by 86%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$7.50

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Consensus revenue estimates increase by 138%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 64%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.63

Consensus forecasts updated

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia®, Inc Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure